FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947900890> ?p ?o ?g. }

• W2947900890 abstract "e14086 Background: PD-1 and PD-L1 inhibitors have now demonstrated their efficacy. Finding predictive or pre-emptive response factors is crucial and the role of immune-related adverse events (irAEs) is widely debated. The aim of our study was to evaluate the correlation between the occurrence of irAEs and overall survival, according to the time of onset. Methods: We retrospectively collected efficacy and safety data from patients treated with nivolumab, pembrolizumab and atezolizumab for metastatic cancer between July 2015 and January 2019 at the Pitié-Salpêtrière Hospital. Progression-free survival (PFS) and overall survival (OS) were analyzed for the global population, for patients who had an irAES, according to the time of onset (before or after 12 weeks). Results: 158 patients were treated with anti-PD1/PD-L1: 125 patients for NSCLC, 12 for melanoma, 11 for clear cell renal cancer, 5 for bladder cancer, 3 for digestive adenocarcinoma and 2 for mesothelioma. At the cut-off analysis, with a median follow-up of 8.6 months, 63 (40%) patients died, 30(19%) had a progressive disease, 31 (20%) were still receiving an immunotherapy. 25(18%) patients developed irAEs, 18(72%) before 12 weeks of treatment and 7(28%) after. 6 patients had to stop the treatment because of irAEs and 3 of them were still on immunotherapy at the cut-off analysis. Progression disease occurred in 7 patients and 9 died under treatment. Only a trend of efficacy was found between patients with irAEs and those without, with a median PFS of 13.2 vs 9.8 months (HR 1.3; p = 0,4) and a median OS of 28 vs 20 months (HR 1.4; p = 0,4). This statistically non-significant trend was found for OS between patients with an early irAEs and those without any toxicity with a median OS of 28 vs 20 months (HR 1.4; p = 0,8). No statistically difference was found between patients with early irAEs and late irAEs. Conclusions: In our study, 18% of the patients had irAEs. Patients with irAEs seemed to have better OS and PFS but no statistically difference was found. This trend is probably related to patients with late toxicity, which reflects the time of treatment and the increasing probability to develop an irAEs. In our study, early irAEs could not be considered as a reliable preemptive factor of response to immunotherapy." @default.
• W2947900890 created "2019-06-07" @default.
• W2947900890 creator A5018725008 @default.
• W2947900890 creator A5020254907 @default.
• W2947900890 creator A5030364688 @default.
• W2947900890 creator A5040139985 @default.
• W2947900890 creator A5047711606 @default.
• W2947900890 creator A5054697519 @default.
• W2947900890 creator A5059607930 @default.
• W2947900890 creator A5085730505 @default.
• W2947900890 date "2019-05-20" @default.
• W2947900890 modified "2023-10-16" @default.
• W2947900890 title "Immunotherapy: Auto-immune toxicity as a predictive factor of response." @default.
• W2947900890 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e14086" @default.
• W2947900890 hasPublicationYear "2019" @default.
• W2947900890 type Work @default.
• W2947900890 sameAs 2947900890 @default.
• W2947900890 citedByCount "0" @default.
• W2947900890 crossrefType "journal-article" @default.
• W2947900890 hasAuthorship W2947900890A5018725008 @default.
• W2947900890 hasAuthorship W2947900890A5020254907 @default.
• W2947900890 hasAuthorship W2947900890A5030364688 @default.
• W2947900890 hasAuthorship W2947900890A5040139985 @default.
• W2947900890 hasAuthorship W2947900890A5047711606 @default.
• W2947900890 hasAuthorship W2947900890A5054697519 @default.
• W2947900890 hasAuthorship W2947900890A5059607930 @default.
• W2947900890 hasAuthorship W2947900890A5085730505 @default.
• W2947900890 hasConcept C126322002 @default.
• W2947900890 hasConcept C143998085 @default.
• W2947900890 hasConcept C203014093 @default.
• W2947900890 hasConcept C2777701055 @default.
• W2947900890 hasConcept C29730261 @default.
• W2947900890 hasConcept C71924100 @default.
• W2947900890 hasConcept C8891405 @default.
• W2947900890 hasConceptScore W2947900890C126322002 @default.
• W2947900890 hasConceptScore W2947900890C143998085 @default.
• W2947900890 hasConceptScore W2947900890C203014093 @default.
• W2947900890 hasConceptScore W2947900890C2777701055 @default.
• W2947900890 hasConceptScore W2947900890C29730261 @default.
• W2947900890 hasConceptScore W2947900890C71924100 @default.
• W2947900890 hasConceptScore W2947900890C8891405 @default.
• W2947900890 hasLocation W29479008901 @default.
• W2947900890 hasOpenAccess W2947900890 @default.
• W2947900890 hasPrimaryLocation W29479008901 @default.
• W2947900890 hasRelatedWork W2292790189 @default.
• W2947900890 hasRelatedWork W2781499826 @default.
• W2947900890 hasRelatedWork W2896068658 @default.
• W2947900890 hasRelatedWork W2898845456 @default.
• W2947900890 hasRelatedWork W2947290678 @default.
• W2947900890 hasRelatedWork W2947666474 @default.
• W2947900890 hasRelatedWork W2952770684 @default.
• W2947900890 hasRelatedWork W2962814122 @default.
• W2947900890 hasRelatedWork W2981649707 @default.
• W2947900890 hasRelatedWork W2996451531 @default.
• W2947900890 hasRelatedWork W3009081800 @default.
• W2947900890 hasRelatedWork W3009288649 @default.
• W2947900890 hasRelatedWork W3016525073 @default.
• W2947900890 hasRelatedWork W3029129345 @default.
• W2947900890 hasRelatedWork W3029793603 @default.
• W2947900890 hasRelatedWork W3126292443 @default.
• W2947900890 hasRelatedWork W3129661963 @default.
• W2947900890 hasRelatedWork W3150345240 @default.
• W2947900890 hasRelatedWork W3163675467 @default.
• W2947900890 hasRelatedWork W3168218042 @default.
• W2947900890 isParatext "false" @default.
• W2947900890 isRetracted "false" @default.
• W2947900890 magId "2947900890" @default.
• W2947900890 workType "article" @default.